FDA Approves Mounjaro for Heart Risk
The US FDA approved Eli Lilly diabetes drug Mounjaro to lower heart attack and stroke risks in adults with type 2 diabetes. The decision expands the drug use beyond blood sugar control following strong trial results.
Xurve View
Insights:
Xurve View
ELI LILLY & CO received United States regulatory approval to market its diabetes treatment Mounjaro for lowering cardiovascular risks in adults. The expanded indication covers patients with type 2 diabetes facing elevated heart attack and stroke hazards. Mounjaro sales surged 91% to $9.94B during the second quarter.
